Answers are grounded in this paper and cite their sources.
Although the Hippo pathway is a well‐established negative regulator of the YAP/TAZ–TEAD1–4 transcriptional complex, the molecular mechanisms that actively sustain YAP/TAZ–TEAD activation remain poorly defined. Integrating recent literature with systematic Cancer Dependency Map (DepMap) codependency analysis, we propose a working model wherein the TAZ/YAP–TEAD complex functions as a nuclear executor of the focal adhesion mechanotransduction cascade. This mechanotransduction arm is predicted to initiate at the plasma membrane by integrins α v β 5 (ITGAV/ITGB5), N‐cadherin (CDH2), and lysophosphatidic acid receptor 1 (LPAR1), which likely engage PKN2 and MARK2/3 signaling kinases downstream of the focal adhesion complex. Conversely, a cell‐surface triad comprising NRP1, PLXNA1, and KIRREL1 and EPHA2 may act as an upstream activator of the inhibitory Hippo pathway. Collectively, we propose that TAZ/YAP–TEAD activity is governed by a dynamic, reciprocal antagonism between the Hippo pathway and focal adhesion‐mediated mechanotransduction, with the latter serving as a positive driver sustaining YAP/TAZ functional activity.
No takes yet. Share an insight, caveat, or question.
Wanjin Hong (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: